<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01043224</url>
  </required_header>
  <id_info>
    <org_study_id>PLQ-004</org_study_id>
    <secondary_id>EudractCT No: 2009-012139-14</secondary_id>
    <nct_id>NCT01043224</nct_id>
  </id_info>
  <brief_title>A Psoriasis Plaque Test Comparing Products for the Treatment of Psoriasis Vulgaris</brief_title>
  <official_title>A Psoriasis Plaque Study Comparing Clobetasol Propionate Plus Calcipotriol Ointment With Clobetasol Propionate Ointment Alone, Calcipotriol Ointment Alone and a Vehicle Control for the Treatment of Psoriasis Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to compare the anti-psoriatic effect of a topical combination
      product containing clobetasol propionate and calcipotriol in an ointment formulation to the
      single components in the same vehicle using a psoriasis plaque test design.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Clinical Score of clinical symptoms</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical scores, lesions thickness, NIR spectroscopic measurements</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>Clobetasol propionate plus calcipotriol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination of clobetasol propionate plus calcipotriol ointment, clobetasol propionate ointment, calcipotriol ointment, and the ointment vehicle</intervention_name>
    <description>Once daily application</description>
    <arm_group_label>Clobetasol propionate plus calcipotriol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (in summary):

          -  Subjects having understood and signed an informed consent form

          -  Either sex

          -  Age 18 years or above

          -  All skin types and any ethnic origin

          -  Subjects with a diagnosis of psoriasis vulgaris with lesions located on arms, legs or
             trunk

        Exclusion Criteria (in summary):

          -  Females who are pregnant, or who wish to become pregnant during the study, or who are
             breast feeding

          -  Systemic treatment with biological therapies (marketed or not marketed) with a
             possible effect on psoriasis vulgaris within 4 weeks (etanercept), 2 months
             (adalimumab, alefacept, infliximab), 4 months (ustekinmab) or 4 weeks/5 half-lives
             (which-ever is longer) for experimental biological products prior to randomisation

          -  Systemic treatments with all other therapies than biologicals, with a potential effect
             on psoriasis vulgaris (e.g., corticosteroids, vitamin D analogues, retinoids,
             immuno-suppressants) within the 4-week period prior to randomisation

          -  Subjects using one of the following topical drugs for the treatment of psoriasis
             within the 4 week period prior to randomisation

               -  Potent or very potent (WHO group III-IV) corticosteroids

               -  PUVA or Grenz ray therapy

          -  Subjects using one of the following topical drugs for the treatment of psoriasis
             within 2 weeks prior to randomisation

               -  WHO group I-II corticosteroids

               -  Topical retinoids

               -  Vitamin D analogues

               -  Topical immunomodulators (e.g. macrolides)

               -  Anthracen derivatives

               -  Tar

               -  Salicylic acid

               -  UVB therapy

          -  Subjects who have received treatment with any non-marketed drug substance (i.e., an
             agent which has not yet been made available for clinical use following registration)
             within the 4 week period prior to randomisation or longer, if the class of the
             substance requires a longer washout as defined above (e.g., biological treatments)

          -  Subjects with current participation in any other interventional clinical, based on
             interview of the subject

          -  Subjects with current diagnosis of guttate, erythrodermic, exfoliative or pustular
             psoriasis

          -  Subjects with known or suspected hypersensitivity to component(s) of the
             investigational products

          -  Subjects with known/suspected disorders of calcium metabolism associated with
             hypercalcaemia

          -  Subjects with known severe hepatic and/or severe renal insufficiency

          -  Subjects with any of the following conditions present on the plaque test areas: viral
             (e.g. herpes or varicella) lesions of the skin, fungal and bacterial skin infections,
             parasitic infections and atrophic skin

          -  Subjects with skin manifestations on the plaque test areas in relation to syphilis or
             tuberculosis, rosacea, perioral dermatitis, acne vulgaris, atrophic skin, striae
             atrophicae, fragility of skin veins, ichthyosis, acne rosacea, ulcers and wounds

          -  Subjects with any concomitant medical or dermatological disorder(s) which might
             preclude accurate evaluation of the psoriasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrice Facy, PhD</last_name>
    <role>Study Director</role>
    <affiliation>LEO Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LEO Pharma site</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2010</study_first_submitted>
  <study_first_submitted_qc>January 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2010</study_first_posted>
  <last_update_submitted>October 24, 2013</last_update_submitted>
  <last_update_submitted_qc>October 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clobetasol</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

